AMRN Stock — Amarin Corporation plc: Cash, EV, Pipeline

Share price

$13.63

Market cap

$287.9M

Cash

$314.6M

Enterprise value

-$26.7M

Balance sheet

Cash	$314.6M
Debt	$0.0M
Net cash	$314.6M
Enterprise value	-$26.7M
Basic shares	420.0M shares
Fully diluted shares	462.9M shares
Fully diluted market cap	$6,309.5M
Cash per share	$0.75

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AMRN daily closes…

Loading price history…

Pipeline assets

Icosapent ethyl

Approved · Active

Aliases VASCEPA, VAZKEPA

Partnerships Seven commercial partners: Edding (China Territory — $25M Recordati-style; tiered double-digit royalties, up to $120M sales milestones), HLS Therapeutics (Canada — up to $47.5M sales milestones + tiered royalties), Biologix (MENA), CSL (Australia/New Zealand), Recordati (59 European countries, Jun 2025 — $25M upfront, up to $150M sales milestones + royalties), Neopharm (Israel), Lotus (ASEAN); Mochida (Jun 2018 collaboration to research/develop new EPA-based products and indications — still early stages, no named asset)

Indications

Severe hypertriglyceridemia (MARINE indication) (Approved)
CV risk reduction in statin-treated high-risk patients (REDUCE-IT indication) (Approved)

Status note Single commercial product; no clinical-stage pipeline in the filing. U.S. FDA approved Jul 2012 (MARINE) and Dec 2019 (REDUCE-IT); EC approved Mar 2021 as VAZKEPA. Several MARINE-indication patents invalidated Mar 2020 (Nevada court; appeals exhausted); generics from Dr. Reddy's and Hikma approved for MARINE indication in U.S.

Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT03428477	Phase 3	Active, not recruiting	Collaborator	Mark A Hull, PhD FRCP	—	Liver Metastasis; Colon Cancer	—
NCT06637657	Not disclosed	Recruiting	Collaborator	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	NVS	Acute Coronary Syndrome	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Mark A Hull, PhD FRCP on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

AMRN — Amarin Corporation plc

Balance sheet

Price history

Pipeline assets

Active clinical trials